Patients With Severe Obesity Are Made Eligible for Complex Abdominal Wall Repair After Preoptimization With GLP-1 Agonists: Results of a Bicentric Pilot Study.

Romain B, Pfirsch V, Manfredelli S, Leroi T, Salman F, Sami O, Westerfeld-Ruillier D, Ledoux S, Moszkowicz D

World journal of surgery15 Mar 2025Cited by 4 (Europe PMC)

PMID40088135PMCIDPMC11994139DOI10.1002/wjs.12547PepBankPUB-40088135

Summary

BackgroundIncisional hernia repairs (IHRs) are not recommended in patients with severe obesity (BMI ≥ 35 kg/m²). Weight loss is challenging, but new medications, such as glucagon-like peptide-1 receptor agonists (GLP-1 agonists), have recently attracted increased attention for their potential weight loss advantages. The aim was to analyze the preliminary results about the safety and weight loss efficiency of the use of GLP-1 agonists in the context of prehabilitation prior to complex IHR.MethodsAll patients planned for IHR with a BMI ≥ 35 kg/m² and treated with preoperative GLP-1 agonists were included in the experimental group and compared with a comparable historical surgical cohort treated with a conventional tailored nutritional preoperative management. Weight loss in the experimental group and perioperative and postoperative outcomes were compared between the two groups. The success rate of GLP1 agonists was defined as a weight loss that enables the patient to fall within the recommended limits of a BMI ≤ 35 kg/m² before an IHR.ResultsFifty-two patients in the control group were compared to 24 with GLP-1 agonists. The distribution of GLP-1 agonists was as follows: semaglutide (n = 12; 50%), dulaglutide (n = 7; 29.2%), and liraglutide (n = 5; 20.8%). The mean initial BMI was 40.1 ± 3.6 kg/m² kg/m². The average percentage of weight loss was 11.3 ± 7.4% with GLP-1 agonists (maximum weight loss was observed with semaglutide 2.4 mg/wk). The success rate of GLP1 agonists (defined as BMI ≤ 35 kg/m² before IHR) was reached for 15/24 patients (62.5%). Postoperative total complication rate was lower in the group with GLP-1 agonists (59.6% in the control group vs. 45.8% in GLP-1 and p = 0.2).ConclusionThis study demonstrated the efficacy of GLP-1 agonists in the optimization of patients with obesity, allowing two thirds of the patients to benefit from IHR, with a tendency for lower morbidity.Trial registrationCPP Mediterranee, n° 21.00430.000004.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study10

1 result from studies that gave the peptide. 1 result from people.

01HumanObservational studyEfficacy outcome
In patients with severe obesity awaiting hernia repair, semaglutide was linked to the maximum weight loss among the studied drugs.
In plain wordsIn patients with severe obesity awaiting hernia repair, semaglutide was linked to the greatest weight loss among the studied drugs.
Peptide
Semaglutide
Outcome
DecreaseMaximum weight loss by drug
Study
n = 24
Comparator
Other GLP-1 agonists
Outcome group
Body weight · Metabolic and weight
Studied dose
2.4 mg/wkAs given in this study (human).
Source sentences
Summary
The average percentage of weight loss was 11.3 ± 7.4% with GLP-1 agonists (maximum weight loss was observed with semaglutide 2.4 mg/wk).
2 context sentences(design, population, supporting numbers)
Summary · context
All patients planned for IHR with a BMI ≥ 35 kg/m² and treated with preoperative GLP-1 agonists were included in the experimental group and compared with a comparable historical surgical cohort treated with a conventional tailored nutritional preoperative management.
Summary · context
The distribution of GLP-1 agonists was as follows: semaglutide (n = 12; 50%), dulaglutide (n = 7; 29.2%), and liraglutide (n = 5; 20.8%).
Show in the study text Report a problemFND-4008813504

Studies that did not test the peptide alone9

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

02HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In hernia repair patients, pooled GLP-1 agonists including dulaglutide showed numerically lower postoperative complications than historical controls, without statistical significance.
In plain wordsIn hernia repair patients, pooled drugs including dulaglutide showed fewer postoperative complications than historical controls, without statistical significance.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changePostoperative total complications
Study
n = 76
Comparator
Historical nutritional management cohort
Outcome group
Adverse events · Whole body
Measurements
Postoperative total complication rate, GLP-1 agonists
45.8%
pooled GLP-1 agonists; p = 0.2
Postoperative total complication rate, control
59.6%
historical control cohort
Source sentences
Summary
Postoperative total complication rate was lower in the group with GLP-1 agonists (59.6% in the control group vs. 45.8% in GLP-1 and p = 0.2).
2 context sentences(design, population, supporting numbers)
Summary · context
All patients planned for IHR with a BMI ≥ 35 kg/m² and treated with preoperative GLP-1 agonists were included in the experimental group and compared with a comparable historical surgical cohort treated with a conventional tailored nutritional preoperative management.
Summary · context
The distribution of GLP-1 agonists was as follows: semaglutide (n = 12; 50%), dulaglutide (n = 7; 29.2%), and liraglutide (n = 5; 20.8%).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-4008813508
03HumanNot a test of Liraglutide aloneObservational studySafety outcome
In hernia repair patients, pooled GLP-1 agonists including liraglutide showed numerically lower postoperative complications than historical controls, without statistical significance.
In plain wordsIn hernia repair patients, pooled drugs including liraglutide showed fewer postoperative complications than historical controls, without statistical significance.
Peptide
Liraglutide
Outcome
No significant changePostoperative total complications
Study
n = 76
Comparator
Historical nutritional management cohort
Outcome group
Adverse events · Whole body
Measurements
Postoperative total complication rate, GLP-1 agonists
45.8%
pooled GLP-1 agonists; p = 0.2
Postoperative total complication rate, control
59.6%
historical control cohort
Source sentences
Summary
Postoperative total complication rate was lower in the group with GLP-1 agonists (59.6% in the control group vs. 45.8% in GLP-1 and p = 0.2).
2 context sentences(design, population, supporting numbers)
Summary · context
All patients planned for IHR with a BMI ≥ 35 kg/m² and treated with preoperative GLP-1 agonists were included in the experimental group and compared with a comparable historical surgical cohort treated with a conventional tailored nutritional preoperative management.
Summary · context
The distribution of GLP-1 agonists was as follows: semaglutide (n = 12; 50%), dulaglutide (n = 7; 29.2%), and liraglutide (n = 5; 20.8%).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4008813509
04HumanNot a test of Semaglutide aloneObservational studySafety outcome
In hernia repair patients, pooled GLP-1 agonists including semaglutide showed numerically lower postoperative complications than historical controls, without statistical significance.
In plain wordsIn hernia repair patients, pooled drugs including semaglutide showed fewer postoperative complications than historical controls, without statistical significance.
Peptide
Semaglutide
Outcome
No significant changePostoperative total complications
Study
n = 76
Comparator
Historical nutritional management cohort
Outcome group
Adverse events · Whole body
Measurements
Postoperative total complication rate, GLP-1 agonists
45.8%
pooled GLP-1 agonists; p = 0.2
Postoperative total complication rate, control
59.6%
historical control cohort
Source sentences
Summary
Postoperative total complication rate was lower in the group with GLP-1 agonists (59.6% in the control group vs. 45.8% in GLP-1 and p = 0.2).
2 context sentences(design, population, supporting numbers)
Summary · context
All patients planned for IHR with a BMI ≥ 35 kg/m² and treated with preoperative GLP-1 agonists were included in the experimental group and compared with a comparable historical surgical cohort treated with a conventional tailored nutritional preoperative management.
Summary · context
The distribution of GLP-1 agonists was as follows: semaglutide (n = 12; 50%), dulaglutide (n = 7; 29.2%), and liraglutide (n = 5; 20.8%).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4008813510
05HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In patients with severe obesity awaiting hernia repair, pooled GLP-1 agonists including dulaglutide were linked to average weight loss of 11.3%.
In plain wordsIn patients with severe obesity awaiting hernia repair, pooled GLP-1 drugs including dulaglutide were linked to average weight loss of 11.3%.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreasePercentage weight loss
Study
n = 24
Outcome group
Body weight · Metabolic and weight
Measurements
Mean percentage weight loss, pooled GLP-1 agonists
11.3%
24 patients on GLP-1 agonists
Standard deviation of percentage weight loss
7.4%
pooled GLP-1 agonists
Source sentences
Summary
The average percentage of weight loss was 11.3 ± 7.4% with GLP-1 agonists (maximum weight loss was observed with semaglutide 2.4 mg/wk).
2 context sentences(design, population, supporting numbers)
Summary · context
All patients planned for IHR with a BMI ≥ 35 kg/m² and treated with preoperative GLP-1 agonists were included in the experimental group and compared with a comparable historical surgical cohort treated with a conventional tailored nutritional preoperative management.
Summary · context
The distribution of GLP-1 agonists was as follows: semaglutide (n = 12; 50%), dulaglutide (n = 7; 29.2%), and liraglutide (n = 5; 20.8%).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-4008813501
06HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In patients with severe obesity awaiting hernia repair, pooled GLP-1 agonists including liraglutide were linked to average weight loss of 11.3%.
In plain wordsIn patients with severe obesity awaiting hernia repair, pooled GLP-1 drugs including liraglutide were linked to average weight loss of 11.3%.
Peptide
Liraglutide
Outcome
DecreasePercentage weight loss
Study
n = 24
Outcome group
Body weight · Metabolic and weight
Measurements
Mean percentage weight loss, pooled GLP-1 agonists
11.3%
24 patients on GLP-1 agonists
Standard deviation of percentage weight loss
7.4%
pooled GLP-1 agonists
Source sentences
Summary
The average percentage of weight loss was 11.3 ± 7.4% with GLP-1 agonists (maximum weight loss was observed with semaglutide 2.4 mg/wk).
2 context sentences(design, population, supporting numbers)
Summary · context
All patients planned for IHR with a BMI ≥ 35 kg/m² and treated with preoperative GLP-1 agonists were included in the experimental group and compared with a comparable historical surgical cohort treated with a conventional tailored nutritional preoperative management.
Summary · context
The distribution of GLP-1 agonists was as follows: semaglutide (n = 12; 50%), dulaglutide (n = 7; 29.2%), and liraglutide (n = 5; 20.8%).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4008813502
07HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In patients with severe obesity awaiting hernia repair, pooled GLP-1 agonists including semaglutide were linked to average weight loss of 11.3%.
In plain wordsIn patients with severe obesity awaiting hernia repair, pooled GLP-1 drugs including semaglutide were linked to average weight loss of 11.3%.
Peptide
Semaglutide
Outcome
DecreasePercentage weight loss
Study
n = 24
Outcome group
Body weight · Metabolic and weight
Measurements
Mean percentage weight loss, pooled GLP-1 agonists
11.3%
24 patients on GLP-1 agonists
Standard deviation of percentage weight loss
7.4%
pooled GLP-1 agonists
Source sentences
Summary
The average percentage of weight loss was 11.3 ± 7.4% with GLP-1 agonists (maximum weight loss was observed with semaglutide 2.4 mg/wk).
2 context sentences(design, population, supporting numbers)
Summary · context
All patients planned for IHR with a BMI ≥ 35 kg/m² and treated with preoperative GLP-1 agonists were included in the experimental group and compared with a comparable historical surgical cohort treated with a conventional tailored nutritional preoperative management.
Summary · context
The distribution of GLP-1 agonists was as follows: semaglutide (n = 12; 50%), dulaglutide (n = 7; 29.2%), and liraglutide (n = 5; 20.8%).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4008813503
08HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In patients awaiting hernia repair, pooled GLP-1 agonists including dulaglutide achieved the preoperative BMI target in 62.5%.
In plain wordsIn patients awaiting hernia repair, pooled GLP-1 drugs including dulaglutide were linked to reaching the preoperative BMI target in 62.5%.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicablePreoperative BMI target success
Study
n = 24
Outcome group
Body weight · Metabolic and weight
Measurements
Success rate (BMI <= 35 kg/m2 before IHR), pooled GLP-1 agonists
62.5%
15 of 24 patients
Patients reaching BMI <= 35 kg/m2
15 patients
of 24 on GLP-1 agonists
Source sentences
Summary
The success rate of GLP1 agonists (defined as BMI ≤ 35 kg/m² before IHR) was reached for 15/24 patients (62.5%).
2 context sentences(design, population, supporting numbers)
Summary · context
All patients planned for IHR with a BMI ≥ 35 kg/m² and treated with preoperative GLP-1 agonists were included in the experimental group and compared with a comparable historical surgical cohort treated with a conventional tailored nutritional preoperative management.
Summary · context
The distribution of GLP-1 agonists was as follows: semaglutide (n = 12; 50%), dulaglutide (n = 7; 29.2%), and liraglutide (n = 5; 20.8%).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-4008813505
09HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In patients awaiting hernia repair, pooled GLP-1 agonists including liraglutide achieved the preoperative BMI target in 62.5%.
In plain wordsIn patients awaiting hernia repair, pooled GLP-1 drugs including liraglutide were linked to reaching the preoperative BMI target in 62.5%.
Peptide
Liraglutide
Outcome
Not applicablePreoperative BMI target success
Study
n = 24
Outcome group
Body weight · Metabolic and weight
Measurements
Success rate (BMI <= 35 kg/m2 before IHR), pooled GLP-1 agonists
62.5%
15 of 24 patients
Patients reaching BMI <= 35 kg/m2
15 patients
of 24 on GLP-1 agonists
Source sentences
Summary
The success rate of GLP1 agonists (defined as BMI ≤ 35 kg/m² before IHR) was reached for 15/24 patients (62.5%).
2 context sentences(design, population, supporting numbers)
Summary · context
All patients planned for IHR with a BMI ≥ 35 kg/m² and treated with preoperative GLP-1 agonists were included in the experimental group and compared with a comparable historical surgical cohort treated with a conventional tailored nutritional preoperative management.
Summary · context
The distribution of GLP-1 agonists was as follows: semaglutide (n = 12; 50%), dulaglutide (n = 7; 29.2%), and liraglutide (n = 5; 20.8%).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4008813506
10HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In patients awaiting hernia repair, pooled GLP-1 agonists including semaglutide achieved the preoperative BMI target in 62.5%.
In plain wordsIn patients awaiting hernia repair, pooled GLP-1 drugs including semaglutide were linked to reaching the preoperative BMI target in 62.5%.
Peptide
Semaglutide
Outcome
Not applicablePreoperative BMI target success
Study
n = 24
Outcome group
Body weight · Metabolic and weight
Measurements
Success rate (BMI <= 35 kg/m2 before IHR), pooled GLP-1 agonists
62.5%
15 of 24 patients
Patients reaching BMI <= 35 kg/m2
15 patients
of 24 on GLP-1 agonists
Source sentences
Summary
The success rate of GLP1 agonists (defined as BMI ≤ 35 kg/m² before IHR) was reached for 15/24 patients (62.5%).
2 context sentences(design, population, supporting numbers)
Summary · context
All patients planned for IHR with a BMI ≥ 35 kg/m² and treated with preoperative GLP-1 agonists were included in the experimental group and compared with a comparable historical surgical cohort treated with a conventional tailored nutritional preoperative management.
Summary · context
The distribution of GLP-1 agonists was as follows: semaglutide (n = 12; 50%), dulaglutide (n = 7; 29.2%), and liraglutide (n = 5; 20.8%).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4008813507

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
22 Oct 2026, 02:25 UTC
Study results updated
Versions 2 to 3
21 Oct 2026, 18:59 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.